FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1967067985> ?p ?o ?g. }

• W1967067985 endingPage "775" @default.
• W1967067985 startingPage "766" @default.
• W1967067985 abstract "Background Fenofibrate is used to treat primary hypercholesterolemia, mixed lipidemia, and hypertriglyceridemia in adults who do not respond to nonpharmacologic measures. Fenofibrate is a prodrug that is rapidly and completely hydrolyzed to fenofibric acid, the active moiety. A new orally administered agent, fenofibric acid, was developed as an alternative to fenofibrate. Objective Two separate studies were conducted to evaluate the bioequivalence of fenofibric acid relative to fenofibrate under fasted and fed (standard breakfast) conditions, characterize the pharmacokinetic profile, and assess the safety and tolerability of fenofibric acid. Methods In study 1 (fasted), during each study period, volunteers received a single 105-mg dose of fenofibric acid or single 145-mg dose of fenofibrate (depending on their randomization scheme) after an overnight fast (a minimum fast of 10 hours). A 7-day washout period followed the first treatment period, after which the volunteers received the alternate treatment. Study 2 followed a similar dosing scheme and differed only in that volunteers received their single dose after being fed a standard meal (575 calories, of which 36% were contributed by fat). Serial blood samples in both studies were collected up to 72 hours after drug administration. The pharmacokinetic parameters of interest for assessing bioequivalence were AUC0–t, AUC0–∞, Cmax, and Tmax. The criterion for a lack of difference between products was a 90% CI between 0.80 and 1.25 for the fenofibric acid:fenofibrate ratios for AUC0–t, AUC0–∞, and Cmax. Tolerability was assessed by adverse events (AEs), laboratory parameters, vital signs, and physical examinations. Results Volunteers in study 1 (fasted; n = 54) were aged 18 to 43 years; 19 (35%) were men and 35 (65%) were women; mean weight was 155.2 pounds (range, 103.0–267.0 pounds); and 48 (89%) were white, 1 (2%) was black, and 5 (9%) were white/American Indian/Alaskan native/Asian. Volunteers in study 2 (fed; n = 54) were aged 18 to 43 years; 27 (50%) were men and 27 (50%) were women; mean weight was 161.9 pounds (range, 112.0–225.0 pounds); and 51 (94%) were white (including 2 Hispanic) and 3 (6%) were black. The 90% CIs about the ratio of the fenofibric acid geometric mean to the fenofibrate geometric mean were within the 80% and 125% limits for the pharmacokinetic parameters Cmax, AUC0–t, and AUC0–∞ of the ln-transformed data in both study 1 (fasted) and study 2. In study 1 (fasted), 14 volunteers (26%) experienced a total of 29 AEs; the most common nonlaboratory AEs were dizziness (6%) and headache (4%). In study 2, 12 volunteers (22%) experienced a total of 19 AEs; the most common nonlaboratory AEs were headache (17%) and dry throat (4%). AEs were generally mild or moderate in intensity. Conclusions In these 2 single-dose studies, these healthy volunteers administered a single oral dose of 105-mg fenofibric acid met the US Food and Drug Administration regulatory criteria for assuming bioequivalence to a single oral dose of 145-mg fenofibrate tablets with respect to the rate and extent of fenofibric acid absorption in both fed and fasted states. Fenofibric acid at the dose studied was well tolerated in this population. ClinicalTrials.gov identifiers: NCT00961116 and NCT00960687." @default.
• W1967067985 created "2016-06-24" @default.
• W1967067985 creator A5029211439 @default.
• W1967067985 creator A5057013016 @default.
• W1967067985 creator A5089720940 @default.
• W1967067985 date "2011-06-01" @default.
• W1967067985 modified "2023-10-16" @default.
• W1967067985 title "Single-Dose Bioequivalence of 105-mg Fenofibric Acid Tablets Versus 145-mg Fenofibrate Tablets Under Fasting and Fed Conditions: A Report of Two Phase I, Open-Label, Single-Dose, Randomized, Crossover Clinical Trials" @default.
• W1967067985 cites W125014100 @default.
• W1967067985 cites W1972484125 @default.
• W1967067985 cites W1991509746 @default.
• W1967067985 cites W1996126594 @default.
• W1967067985 cites W2005965794 @default.
• W1967067985 cites W2013209414 @default.
• W1967067985 cites W2082680963 @default.
• W1967067985 cites W4240494060 @default.
• W1967067985 doi "https://doi.org/10.1016/j.clinthera.2011.05.047" @default.
• W1967067985 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21704241" @default.
• W1967067985 hasPublicationYear "2011" @default.
• W1967067985 type Work @default.
• W1967067985 sameAs 1967067985 @default.
• W1967067985 citedByCount "10" @default.
• W1967067985 countsByYear W19670679852012 @default.
• W1967067985 countsByYear W19670679852013 @default.
• W1967067985 countsByYear W19670679852014 @default.
• W1967067985 countsByYear W19670679852016 @default.
• W1967067985 countsByYear W19670679852020 @default.
• W1967067985 countsByYear W19670679852023 @default.
• W1967067985 crossrefType "journal-article" @default.
• W1967067985 hasAuthorship W1967067985A5029211439 @default.
• W1967067985 hasAuthorship W1967067985A5057013016 @default.
• W1967067985 hasAuthorship W1967067985A5089720940 @default.
• W1967067985 hasConcept C112705442 @default.
• W1967067985 hasConcept C142724271 @default.
• W1967067985 hasConcept C197934379 @default.
• W1967067985 hasConcept C204787440 @default.
• W1967067985 hasConcept C22979827 @default.
• W1967067985 hasConcept C27081682 @default.
• W1967067985 hasConcept C2778110834 @default.
• W1967067985 hasConcept C2778375690 @default.
• W1967067985 hasConcept C42404028 @default.
• W1967067985 hasConcept C71924100 @default.
• W1967067985 hasConcept C87813604 @default.
• W1967067985 hasConcept C98274493 @default.
• W1967067985 hasConceptScore W1967067985C112705442 @default.
• W1967067985 hasConceptScore W1967067985C142724271 @default.
• W1967067985 hasConceptScore W1967067985C197934379 @default.
• W1967067985 hasConceptScore W1967067985C204787440 @default.
• W1967067985 hasConceptScore W1967067985C22979827 @default.
• W1967067985 hasConceptScore W1967067985C27081682 @default.
• W1967067985 hasConceptScore W1967067985C2778110834 @default.
• W1967067985 hasConceptScore W1967067985C2778375690 @default.
• W1967067985 hasConceptScore W1967067985C42404028 @default.
• W1967067985 hasConceptScore W1967067985C71924100 @default.
• W1967067985 hasConceptScore W1967067985C87813604 @default.
• W1967067985 hasConceptScore W1967067985C98274493 @default.
• W1967067985 hasIssue "6" @default.
• W1967067985 hasLocation W19670679851 @default.
• W1967067985 hasLocation W19670679852 @default.
• W1967067985 hasOpenAccess W1967067985 @default.
• W1967067985 hasPrimaryLocation W19670679851 @default.
• W1967067985 hasRelatedWork W124377181 @default.
• W1967067985 hasRelatedWork W151882183 @default.
• W1967067985 hasRelatedWork W2025400670 @default.
• W1967067985 hasRelatedWork W2087796686 @default.
• W1967067985 hasRelatedWork W2431224659 @default.
• W1967067985 hasRelatedWork W2787516851 @default.
• W1967067985 hasRelatedWork W2807216939 @default.
• W1967067985 hasRelatedWork W2950351041 @default.
• W1967067985 hasRelatedWork W4296918699 @default.
• W1967067985 hasRelatedWork W2187179074 @default.
• W1967067985 hasVolume "33" @default.
• W1967067985 isParatext "false" @default.
• W1967067985 isRetracted "false" @default.
• W1967067985 magId "1967067985" @default.
• W1967067985 workType "article" @default.